Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
about
Latest developments and future directions in dengue vaccinesRecent advances of vaccine adjuvants for infectious diseasesImmunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in miceA New Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL-2+ T Cells.Raising expectations for subunit vaccineMammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractComparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton ratsA review of clinical trials of human papillomavirus prophylactic vaccines.Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccinesParticulate inorganic adjuvants: recent developments and future outlook.Recent progress in dengue vaccine development.Strategies for designing synthetic immune agonists.Vaccines, reverse vaccinology, and bacterial pathogenesis.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.New adjuvants in evolving vaccine strategies.Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.Monophosphoryl lipid A-induced pro-inflammatory cytokine expression does not require CD14 in primary human dendritic cells.
P2860
Q27023422-6A6E8006-34F0-4F7B-87CA-E68B9485F169Q28083679-478BB4E7-3BFF-4D81-9311-F30C46350E73Q28730052-4035B66A-09D2-46DF-A8C9-7DC70BFBA9F3Q33703027-8C8A78C7-07CE-4479-AD6E-B28EF5634D70Q35452705-8EBD2AAE-DD4E-4E55-A712-D13593708DEEQ35690781-579AE466-AF63-40C4-A02E-902732F4FD51Q35886534-DD16D65B-1BD4-4698-95E2-AB9D8F8DD6F8Q36251566-732B9A3C-11B9-4AC1-AAED-440D15CC3F04Q36259403-A517060E-7945-4620-8C47-68B055D452BDQ37135012-E4526C2B-ED10-46D0-9035-152D17F3DFC4Q38286377-53A8E7E0-8026-43B3-9CC9-8F89E0BE29B6Q38303232-68EE416C-543F-4968-BB48-413EF450DA05Q38841677-21D81E80-EE94-48B6-BA97-62EA96A82736Q39426398-5891679B-FE1C-4B53-BAA1-F83F827CA8F9Q47549756-30A615E2-6ABA-405C-9D11-1DE9EF24E576Q51007398-4B58D103-D67F-443A-A1C9-25BD134CA160Q51743232-AA1C6E6A-66E3-40AE-A8B0-73D766C3B141Q52879746-C83B52DD-C04D-4B82-8136-608808053D5A
P2860
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
@en
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
@nl
type
label
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
@en
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
@nl
prefLabel
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
@en
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
@nl
P2093
P2860
P1476
Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
@en
P2093
Marcelle Van Mechelen
Martine Wettendorff
Nathalie Garçon
P2860
P304
P356
10.1517/14712598.2011.573624
P407
P577
2011-04-04T00:00:00Z